<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR16">
 <label>16.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Hocqueloux</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Raffi</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Prazuck</surname>
    <given-names>T</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Dolutegravir Monotherapy versus Dolutegravir/Abacavir/lamivudine for Virologically suppressed people living with chronic human immunodeficiency virus infection: the randomized noninferiority MONotherapy of TiviCAY trial</article-title>
  <source>Clin Infect Dis</source>
  <year>2019</year>
  <volume>69</volume>
  <issue>9</issue>
  <fpage>1498</fpage>
  <lpage>1505</lpage>
  <pub-id pub-id-type="doi">10.1093/cid/ciy1132</pub-id>
  <?supplied-pmid 30601976?>
  <pub-id pub-id-type="pmid">30601976</pub-id>
 </element-citation>
</ref>
